Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, recently announced the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb’s effectiveness in weight loss and muscle preservation. In the brand’s fourth human clinical study users saw an average weight loss of 8.3 lbs (3.77 kg) after six months of consistent use paired with ‘real world’ healthy diet and exercise advice. There was no loss in muscle mass.
Calocurb is derived from a patented bitter hops extract called Amarasate®, first identified as part of an extensive research programme funded by the New Zealand government. Unlike prescription GLP-1 medications, Calocurb works by significantly stimulating 3 of the body’s own natural satiety hormones (GLP-1, CCK, PYY) by activating bitter taste receptors in the L-cells of the gastrointestinal tract, to reduce hunger, cravings and calorie intake.
The randomized, double-blind clinical trial undertaken by a research institute of the New Zealand government, evaluated Calocurb over 24 weeks with a three-month follow-up on all participants. Those who took Calocurb experienced significantly greater reductions in body weight, body fat, and visceral fat, and also maintained muscle mass, compared to the placebo group. This is a major feat in the weight management space, as synthetic GLP-1 medications have been shown to decrease muscle mass, potentially leading to long-term issues with mobility and bone health. Key results from Calocurb’s fourth human clinical study include the following:
- Calocurb is clinically shown to improve body composition by reducing body fat without losing muscle mass
- Average weight loss of 8.3 lbs (3.77 kg) after six months, compared to 0.88 lbs (0.4 kg) with the placebo group
- Over 6.5x greater reduction in body fat vs placebo
- Average body fat loss of 9.9 lbs (4.49 kg) vs 1.5 lbs (0.68 kg) after six months of consistent use of Calocurb vs placebo
- 3.5x greater reduction in visceral fat vs placebo
- Average visceral fat loss of 5 in2 (32.5 cm2) vs 1.4 in2 (9.1 cm2) lost after six months of consistent use of Calocurb vs placebo
For over a decade, Calocurb has undertaken ground-breaking clinical research into Amarasate® to continue bringing natural weight management solutions to those interested in GLP-1 and weight loss options.
“The new clinical data proves not only Calocurb’s contribution to weight loss overall, but also muscle preservation, which is groundbreaking in the crowded space of GLP-1s and other weight reduction options,” said Sarah Kennedy, Founder and CEO of Calocurb. “From our years of research, we knew Calocurb was life-changing for so many, but now we are very excited to present independent clinical data to show its effectiveness across the board to improve body composition, while being 100% natural.”
As the world’s first natural GLP-1 option clinically proven to facilitate weight loss, Calocurb opens new doors for individuals on a weight management journey. Rooted in overall wellness, science, and effectiveness, these new strides will equip practitioners, patients, and consumers with the tools and knowledge to build a healthier population.
